316 related articles for article (PubMed ID: 2471782)
1. Host cell selection of antigenic variants of foot-and-mouth disease virus.
Bolwell C; Brown AL; Barnett PV; Campbell RO; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ
J Gen Virol; 1989 Jan; 70 ( Pt 1)():45-57. PubMed ID: 2471782
[TBL] [Abstract][Full Text] [Related]
2. Selection of antigenic variants of foot-and-mouth disease virus in the absence of antibodies, as revealed by an in situ assay.
Diez J; Mateu MG; Domingo E
J Gen Virol; 1989 Dec; 70 ( Pt 12)():3281-9. PubMed ID: 2481712
[TBL] [Abstract][Full Text] [Related]
3. Epitope mapping of foot-and-mouth disease virus with neutralizing monoclonal antibodies.
Bolwell C; Clarke BE; Parry NR; Ouldridge EJ; Brown F; Rowlands DJ
J Gen Virol; 1989 Jan; 70 ( Pt 1)():59-68. PubMed ID: 2471783
[TBL] [Abstract][Full Text] [Related]
4. Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies.
Stave JW; Card JL; Morgan DO
J Gen Virol; 1986 Oct; 67 ( Pt 10)():2083-92. PubMed ID: 2428926
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.
Parry NR; Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F
J Gen Virol; 1989 Jun; 70 ( Pt 6)():1493-503. PubMed ID: 2471812
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies to an Indian strain of type A foot-and-mouth disease virus.
Tosh C; Venkataramanan R; Pattnaik B; Hemadri D; Sanyal A
Acta Virol; 1999 Aug; 43(4):219-25. PubMed ID: 10749367
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse.
Barnett PV; Samuel AR; Pullen L; Ansell D; Butcher RN; Parkhouse RM
J Gen Virol; 1998 Jul; 79 ( Pt 7)():1687-97. PubMed ID: 9680132
[TBL] [Abstract][Full Text] [Related]
8. Generation of a subtype-specific neutralization epitope in foot-and-mouth disease virus of a different subtype.
Hernández J; Martínez MA; Rocha E; Domingo E; Mateu MG
J Gen Virol; 1992 Jan; 73 ( Pt 1)():213-6. PubMed ID: 1370534
[TBL] [Abstract][Full Text] [Related]
9. Multiple variants in foot-and-mouse disease virus (FMDV) populations: the Achilles heel for peptide and rec. DNA vaccines?
Barteling SJ; Woortmeyer R
Dev Biol Stand; 1987; 66():511-21. PubMed ID: 3034708
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites.
Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F; Parry NR
J Gen Virol; 1989 Jun; 70 ( Pt 6)():1483-91. PubMed ID: 2471811
[TBL] [Abstract][Full Text] [Related]
11. Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants.
Saiz JC; Gonzalez MJ; Borca MV; Sobrino F; Moore DM
J Virol; 1991 May; 65(5):2518-24. PubMed ID: 1707983
[TBL] [Abstract][Full Text] [Related]
12. Distinct repertoire of antigenic variants of foot-and-mouth disease virus in the presence or absence of immune selection.
Borrego B; Novella IS; Giralt E; Andreu D; Domingo E
J Virol; 1993 Oct; 67(10):6071-9. PubMed ID: 7690417
[TBL] [Abstract][Full Text] [Related]
13. Escape mutants of foot-and-mouth disease virus selected by monoclonal antibodies directed to a trypsin-sensitive neutralization epitope.
Das BR; Pattnaik B; Venkataramanan R; Rai DV
Acta Virol; 1997 Jun; 41(3):131-8. PubMed ID: 9385400
[TBL] [Abstract][Full Text] [Related]
14. A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C.
Mateu MG; Martínez MA; Capucci L; Andreu D; Giralt E; Sobrino F; Brocchi E; Domingo E
J Gen Virol; 1990 Mar; 71 ( Pt 3)():629-37. PubMed ID: 1690261
[TBL] [Abstract][Full Text] [Related]
15. Reactivity with monoclonal antibodies of viruses from an episode of foot-and-mouth disease.
Mateu MG; Rocha E; Vicente O; Vayreda F; Navalpotro C; Andreu D; Pedroso E; Giralt E; Enjuanes L; Domingo E
Virus Res; 1987 Sep; 8(3):261-74. PubMed ID: 2446442
[TBL] [Abstract][Full Text] [Related]
16. Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus.
Baxt B; Vakharia V; Moore DM; Franke AJ; Morgan DO
J Virol; 1989 May; 63(5):2143-51. PubMed ID: 2467993
[TBL] [Abstract][Full Text] [Related]
17. Response of foot-and-mouth disease virus C3 Resende to immunological pressure exerted in vitro by antiviral polyclonal sera.
Schiappacassi M; Rieder Rojas E; Carrillo E; Campos R
Virus Res; 1995 Apr; 36(1):77-85. PubMed ID: 7542827
[TBL] [Abstract][Full Text] [Related]
18. Analysis of neutralizing epitopes on foot-and-mouth disease virus.
Pfaff E; Thiel HJ; Beck E; Strohmaier K; Schaller H
J Virol; 1988 Jun; 62(6):2033-40. PubMed ID: 2835507
[TBL] [Abstract][Full Text] [Related]
19. Characterization of monoclonal antibodies against a type SAT 2 foot-and-mouth disease virus.
Crowther JR; Rowe CA; Butcher R
Epidemiol Infect; 1993 Oct; 111(2):391-406. PubMed ID: 7691630
[TBL] [Abstract][Full Text] [Related]
20. A high proportion of anti-peptide antibodies recognize foot-and-mouth disease virus particles.
Parry NR; Syred A; Rowlands DJ; Brown F
Immunology; 1988 Aug; 64(4):567-72. PubMed ID: 2844657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
